Episode 392: Aspirin – two more large and maybe unnecessary trials
In episode 392, James and Mike get back to work after a European tour and other reasons. We go over the results from the latest large aspirin trials and, low and behold, the results show pretty much what we already knew.
Show notes
1) Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial.
Lancet 2018 Aug 24. pii: S0140-6736
2) Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus
N Engl J Med. 2018 Aug 26. doi: 10.1056/NEJMoa1804988
3) The best CVD risk calculator
Listening to this episode is for premium podcast members only. If you already have a membership, login to your account. If you aren't yet a premium subscriber, sign up today!
